ImmunoGen To Focus Operations On Mivetuximab Soravtansine Development

ImmunoGen IMGN focuses on antibody-drug conjugates for the treatment of cancer and the company said Thursday it will prioritize continued development of “Mivetuximab Soravtansine” targeting solid tumors

Mirvetuximab Soravtansine is a potential new treatment for patients with folate receptor alpha (FRα)-positive cancer.

ImmunoGen shares traded lwoer by 1.5% to $1.90 at time of publication.

Related Links:

Acer Therapeutics Shares Plunge On FDA Complete Response Letter

Pfizer Receives European Commission Approval For Breast Cancer Drug TALZENNA